Search research articles
Contact Us
Filters
Showing results (71-80 of 101) with videos related to
Page
of 11
Sort By:
The Prostate
|
July 27, 2025
Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor
Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, et al.
Translational Andrology and Urology
|
September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab
Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Clinical Oncology
|
October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Cancers
|
August 28, 2025
Urinary microRNAs as Prognostic Biomarkers for Predicting the Efficacy of Immune Checkpoint Inhibitors in Patients with Urothelial Carcinoma
Yosuke Hirasawa, Atsushi Satomura, Mitsuo Okada, et al.
In Vivo (Athens, Greece)
|
April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin
Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
December 19, 2023
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
Wataru Fukuokaya, Yuhei Koike, Yuji Yata, et al.
Urologic Oncology
|
May 5, 2019
C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - A data from multi-institutional study in Japan
Takuya Tsujino, Kazumasa Komura, Takeshi Hashimoto, et al.
Japanese Journal of Clinical Oncology
|
November 26, 2014
Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib
Tsunenori Kondo, Hayakazu Nakazawa, Mototsugu Oya, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 20, 2025
Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study
Takuhisa Nukaya, Kiyoshi Takahara, Shingo Toyoda, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 101) with videos related to
Sort By:
Page
of 11
The Prostate
|
July 27, 2025
Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor
Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, et al.
Translational Andrology and Urology
|
September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab
Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Clinical Oncology
|
October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Cancers
|
August 28, 2025
Urinary microRNAs as Prognostic Biomarkers for Predicting the Efficacy of Immune Checkpoint Inhibitors in Patients with Urothelial Carcinoma
Yosuke Hirasawa, Atsushi Satomura, Mitsuo Okada, et al.
In Vivo (Athens, Greece)
|
April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin
Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
December 19, 2023
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
Wataru Fukuokaya, Yuhei Koike, Yuji Yata, et al.
Urologic Oncology
|
May 5, 2019
C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - A data from multi-institutional study in Japan
Takuya Tsujino, Kazumasa Komura, Takeshi Hashimoto, et al.
Japanese Journal of Clinical Oncology
|
November 26, 2014
Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib
Tsunenori Kondo, Hayakazu Nakazawa, Mototsugu Oya, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 20, 2025
Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study
Takuhisa Nukaya, Kiyoshi Takahara, Shingo Toyoda, et al.
Page
of 11